Results 191 to 199 of about 1,585,431 (199)

Evaluation of a novel EHR sidecar application to display RA clinical outcomes during clinic visits: results of a stepped‐wedge cluster randomized pragmatic trial

Arthritis Care &Research, Accepted Article.
Objective We developed a novel EHR sidecar application to visualize key rheumatoid arthritis (RA) outcomes, including disease activity, physical function, and pain, via a patient‐facing graphical interface designed for use during outpatient visits (“RA PRO dashboard”).
Gabriela Schmajuk, Jing Li, Cathy Nasrallah, Cherish Wilson, Alicia Hamblin, Christine Hariz, Cammie Young, Stephen Shiboski, Emma Kersey, Mary Nakamura, Judith F. Ashouri, Mehrdad Matloubian, Andrew J. Gross, Jennifer Barton, Beth Berrean, Jonathan Prugh, Jinoos Yazdany   +16 more
wiley   +1 more source

Pipeline for development of acylated peptide based CGRP receptor antagonist with extended half-life for migraine treatment. [PDF]

Sci Rep
Kristensen JB, Elster L, Lundh M, Ballarín-González B, Alexopoulou F, Kræmer M, Jensen DM, Leurs U, Nielsen JC, Hansen HH, Haanes KA, Degn M.   +11 more
europepmc   +1 more source

Enhanced plasma half-life and efficacy of engineered human albumin-fused GLP-1 despite enzymatic cleavage of its C-terminal end. [PDF]

Commun Biol
Nilsen J, Aaen KH, Benjakul S, Ruso-Julve F, Greiner TU, Bejan D, Stensland M, Singh S, Schlothauer T, Sandlie I, Andersen JT.   +10 more
europepmc   +1 more source

Intracellular islatravir-triphosphate half-life supports extended dosing intervals. [PDF]

Antimicrob Agents Chemother
Zang X, Ankrom W, Kraft WK, Vargo R, Stoch SA, Iwamoto M, Matthews RP.   +6 more
europepmc   +1 more source

Superior Prophylactic Effectiveness of a Recombinant FVIIIFc Over Standard Half-Life FVIII in Hemophilia A: A-SURE Study. [PDF]

Eur J Haematol
Oldenburg J, Hay C, Peyvandi F, Tagliaferri A, Holme PA, Álvarez-Román MT, Biron-Andréani C, Malmström H, Bystrická L, Lethagen S, A‐SURE Study Group.   +10 more
europepmc   +1 more source

Revolutionizing Heart Failure Therapy: Harnessing IVT mRNA and Fusion Protein Technology to Prolong rhBNP Half-Life. [PDF]

Pharm Res
Guo Y, Sun T, Li M, Chen Z, Liu Y, Luo X, Chen Y, Li Y, Kuai L, Yu X, Zou L.   +10 more
europepmc   +1 more source